Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)

Status:
Completed

Trial end date:
2011-05-01

Target enrollment:

Participant gender:

This study will use imaging to look at tumor response to erlotinib (Part I) and the combination of erlotinib and dalotuzumab (Part II).

Phase 1

Merck Sharp & Dohme Corp.

Antibodies, Monoclonal
Erlotinib Hydrochloride